The high dose (200 μg) anti-PD-1 mAb demonstrates the most pronounced inhibitory effects on both size of primary tumor growth and number of pulmonary metastasis (Fig. 2E), compared to a low dose (12.5 μg). The gene discussed is PDCD1; the disease is neoplasm.